| Mcr Health, Inc. | |
|
725 N 12th Ave Arcadia FL 34266-8752 | |
| (863) 494-1242 | |
| (863) 491-0466 |
| Full Name | Mcr Health, Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 725 N 12th Ave, Arcadia, Florida |
| Authorized Official Name and Position | Melvin B Price (PRESIDENT AND CEO) |
| Authorized Official Contact | 9417764000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mcr Health, Inc. 101 Riverfront Blvd Ste 710 Bradenton FL 34205-8812 Ph: (941) 776-4000 | Mcr Health, Inc. 725 N 12th Ave Arcadia FL 34266-8752 Ph: (863) 494-1242 |
| NPI Number | 1770989683 |
|---|---|
| Provider Enumeration Date | 11/05/2014 |
| Last Update Date | 03/08/2024 |
| Certification Date | 03/08/2024 |
| Medicare PECOS PAC ID | 7214847995 |
|---|---|
| Medicare Enrollment ID | O20150825003439 |
News Archive
Substance misuse, although common among people with schizophrenia, does not heighten their risk for self-harm or violence, study findings show.
Writing as a component of a clinical course of therapy improves results and allows patients to recover more quickly. Doctoral candidate Peggy Penn concludes this in her thesis, which she defended on Monday June 2nd at Tilburg University in the Netherlands.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
Treatment with sertraline may provide nominal but important improvements in cognition and social participation in very young children with fragile X syndrome, the most common genetic cause of intellectual disability and the leading single-gene cause of autism, a study by researchers with the UC Davis MIND Institute has found.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770989683 | NPI | - | NPPES |
News Archive
Substance misuse, although common among people with schizophrenia, does not heighten their risk for self-harm or violence, study findings show.
Writing as a component of a clinical course of therapy improves results and allows patients to recover more quickly. Doctoral candidate Peggy Penn concludes this in her thesis, which she defended on Monday June 2nd at Tilburg University in the Netherlands.
Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.
Treatment with sertraline may provide nominal but important improvements in cognition and social participation in very young children with fragile X syndrome, the most common genetic cause of intellectual disability and the leading single-gene cause of autism, a study by researchers with the UC Davis MIND Institute has found.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
› Verified 1 days ago
Mcr Health, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 707 N 12th Ave, Arcadia, FL 34266 Phone: 863-494-1242 Fax: 863-491-0466 | |
Drug-free Desoto Coalition Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 530 Lasolona Ave, Arcadia, FL 34266 Phone: 863-494-4222 | |
Mcr Health, Inc. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1148 E Gibson St, Arcadia, FL 34266 Phone: 863-494-6222 Fax: 941-708-8893 | |
Community Care Family Clini Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 725 N 12th Ave, Arcadia, FL 34266 Phone: 863-494-1242 Fax: 863-491-0466 | |
Direct Access Counseling And Supportive Services Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 223 E Oak St Apt 3, Arcadia, FL 34266 Phone: 239-652-0260 Fax: 239-652-0146 | |
Mcr Health, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 707 N 12th Ave, Arcadia, FL 34266 Phone: 863-494-1242 | |
Mcr Health, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 725 N 12th Ave, Arcadia, FL 34266 Phone: 863-494-1242 Fax: 863-491-0466 |